Literature DB >> 22740488

Revisiting the multiple sclerosis functional composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures.

D Ontaneda1, N LaRocca, T Coetzee, Ra Rudick.   

Abstract

This article describes proceedings from a meeting of the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures (the TF). The TF was appointed by the NMSS Research Programs Advisory Committee with the goal of pooling and analyzing existing datasets to explore the utility of novel disability outcome measures based on the Multiple Sclerosis Functional Composite (MSFC) approach. The TF seeks to determine the suitability of the MSFC approach as a primary clinical outcome measure for registration trials in MS. The TF met in Washington, DC, Dec. 14 and 15, 2011, and provided unanimous support for a collaborative approach involving representatives from academic medicine, the pharmaceutical industry, regulatory agencies, the NMSS and the Critical Path Institute. There was also unanimous agreement that analysis of existing datasets would be useful in making progress toward the objective. The TF placed high value on determining the clinical meaning of individual component measures for the MSFC, and in establishing optimal analysis methods for MSFC so that scores would be more interpretable than the originally recommended z-score method. The background for a collaborative project aimed at developing an improved disability outcome measure is described in this paper.

Entities:  

Mesh:

Year:  2012        PMID: 22740488     DOI: 10.1177/1352458512451512

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  24 in total

1.  Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression.

Authors:  Robert Küffner; Neta Zach; Raquel Norel; Johann Hawe; David Schoenfeld; Liuxia Wang; Guang Li; Lilly Fang; Lester Mackey; Orla Hardiman; Merit Cudkowicz; Alexander Sherman; Gokhan Ertaylan; Moritz Grosse-Wentrup; Torsten Hothorn; Jules van Ligtenberg; Jakob H Macke; Timm Meyer; Bernhard Schölkopf; Linh Tran; Rubio Vaughan; Gustavo Stolovitzky; Melanie L Leitner
Journal:  Nat Biotechnol       Date:  2014-11-02       Impact factor: 54.908

Review 2.  The promise of futility trials in neurological diseases.

Authors:  Marcus W Koch; Lawrence Korngut; David G Patry; Yahya Agha-Khani; Christopher White; Justyna R Sarna; Michael Yeung; V Wee Yong; Daniel Y C Heng; Gary Cutter; Luanne Metz
Journal:  Nat Rev Neurol       Date:  2015-03-17       Impact factor: 42.937

3.  Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.

Authors:  Robert J Fox; Christopher S Coffey; Robin Conwit; Merit E Cudkowicz; Trevis Gleason; Andrew Goodman; Eric C Klawiter; Kazuko Matsuda; Michelle McGovern; Robert T Naismith; Akshata Ashokkumar; Janel Barnes; Dixie Ecklund; Elizabeth Klingner; Maxine Koepp; Jeffrey D Long; Sneha Natarajan; Brenda Thornell; Jon Yankey; Robert A Bermel; Josef P Debbins; Xuemei Huang; Patricia Jagodnik; Mark J Lowe; Kunio Nakamura; Sridar Narayanan; Ken E Sakaie; Bhaskar Thoomukuntla; Xiaopeng Zhou; Stephen Krieger; Enrique Alvarez; Michelle Apperson; Khurram Bashir; Bruce A Cohen; Patricia K Coyle; Silvia Delgado; L Dana Dewitt; Angela Flores; Barbara S Giesser; Myla D Goldman; Burk Jubelt; Neil Lava; Sharon G Lynch; Harold Moses; Daniel Ontaneda; Jai S Perumal; Michael Racke; Pavle Repovic; Claire S Riley; Christopher Severson; Shlomo Shinnar; Valerie Suski; Bianca Weinstock-Guttman; Vijayshree Yadav; Aram Zabeti
Journal:  N Engl J Med       Date:  2018-08-30       Impact factor: 91.245

Review 4.  Progressive multiple sclerosis.

Authors:  Daniel Ontaneda; Robert J Fox
Journal:  Curr Opin Neurol       Date:  2015-06       Impact factor: 5.710

Review 5.  Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives.

Authors:  Daniel Ontaneda; Robert J Fox; Jeremy Chataway
Journal:  Lancet Neurol       Date:  2015-02       Impact factor: 44.182

Review 6.  Treatment trials in progressive MS--current challenges and future directions.

Authors:  Marcus W Koch; Gary Cutter; Peter K Stys; V Wee Yong; Luanne M Metz
Journal:  Nat Rev Neurol       Date:  2013-07-30       Impact factor: 42.937

Review 7.  Impact of Pharmacotherapy on Cognitive Dysfunction in Patients with Multiple Sclerosis.

Authors:  Shumita Roy; Ralph H B Benedict; Allison S Drake; Bianca Weinstock-Guttman
Journal:  CNS Drugs       Date:  2016-03       Impact factor: 5.749

8.  Technology-enabled assessments to enhance multiple sclerosis clinical care and research.

Authors:  Gabrielle Macaron; Brandon P Moss; Hong Li; Laura E Baldassari; Stephen M Rao; David Schindler; Jay L Alberts; Malory Weber; Malissa Ayers; François Bethoux; Adrienne Boissy; Desiree Chizmadia; Devon S Conway; Charlene Fink; Robert J Fox; Shauna Gales; Bethany Green; Claire Hara-Cleaver; Neal Jordan; Kedar R Mahajan; Marisa P McGinley; Deborah M Miller; Marie Namey; Alexander Rae-Grant; Mary Rensel; Hilary Young; Mary A Willis; Daniel Ontaneda; Jeffrey A Cohen; Robert A Bermel
Journal:  Neurol Clin Pract       Date:  2020-06

Review 9.  Standardization and digitization of clinical data in multiple sclerosis.

Authors:  Marcus D'Souza; Athina Papadopoulou; Christophe Girardey; Ludwig Kappos
Journal:  Nat Rev Neurol       Date:  2021-01-15       Impact factor: 42.937

Review 10.  Outcome measures in relapsing-remitting multiple sclerosis: capturing disability and disease progression in clinical trials.

Authors:  Amy M Lavery; Leonard H Verhey; Amy T Waldman
Journal:  Mult Scler Int       Date:  2014-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.